scholarly journals PDG34 META-ANALYSIS AND COST-EFFECTIVENESS ANALYSIS OF INSULIN GLARGINE 100 U/ML VERSUS INSULIN DEGLUDEC FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS

2019 ◽  
Vol 22 ◽  
pp. S168
Author(s):  
W. Su ◽  
C. Li ◽  
L. Zhang ◽  
Z. Lin ◽  
J. Tan ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cost Effectiveness ◽  
Insulin Glargine ◽  
Meta Analysis ◽  
Cost Effectiveness Analysis ◽  
Insulin Degludec ◽  
Effectiveness Analysis

Validation of the pharmacoeconomic model of cost-effectiveness analysis of insulin degludec (Tresiba®) in comparison with the insulin glargine u300 in the treatment of type 2 diabetes mellitus in the Russian Federation

2021 ◽  
Vol 9 (3) ◽  
pp. 11-16
Author(s):  
M.V. Globin ◽  
A.Y. Kulikov ◽  
A.A. Litvinova ◽  
V.G. Serpik
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cost Effectiveness ◽  
Insulin Glargine ◽  
Insulin Degludec ◽  
Effectiveness Analysis ◽  
Pharmacoeconomic Model ◽  
The Russian Federation

The global pharmacoeconomic model of cost-effectiveness analysis of insulin degludec (Tresiba®) use in comparison with insulin glargine U300 in the treatment of type 2 diabetes mellitus, was validated. As the result, it was found that the model is relevant to local clinical practice, fully complies with the pharmacoeconomics methodology, takes into account the entire spectrum of costs relevant for the pharmacoeconomic evaluation of insulin in Russia, and the computations built in it is correct. Based on the actual cost data entered, the model calculated the ICER of degludec insulin, which was 214,714 rubles, which does not exceed the sum of three GDP per capita – 2,184,562 rubles and corresponds to the willingness to pay threshold in the Russian Federation. Thus, the insulin degludec (Tresiba®) can be considered as cost-effective from the standpoint of the conducted pharmacoeconomic analysis.

scholarly journals Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus

2019 ◽  
Vol 4 (2) ◽  
pp. 277-286 ◽  
Author(s):  
Margarita Capel ◽  
Andreea Ciudin ◽  
María Mareque ◽  
Raquel María Rodríguez-Rincón ◽  
Susana Simón ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cost Effectiveness ◽  
Cost Effectiveness Analysis ◽  
Receptor Agonists ◽  
Effectiveness Analysis

Intensive versus conventional treatment on patients with type-2 diabetes mellitus. A cost/effectiveness analysis

2015 ◽  
Vol 241 (1) ◽  
pp. e215
Author(s):  
M. Hernandez-Sanchez ◽  
C. Fernandez-Fernandez ◽  
A. Rodriguez-Guerrero ◽  
L. Martín-Fernandez ◽  
D. Barrio-Carreras ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cost Effectiveness ◽  
Conventional Treatment ◽  
Cost Effectiveness Analysis ◽  
Effectiveness Analysis

scholarly journals Pharmacoeconomic aspects of the use of sulfonylurea drugs in type 2 diabetes mellitus

2011 ◽  
Vol 14 (3) ◽  
pp. 111-112
Author(s):  
Alla Vsevolodovna Rudakova
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cost Effectiveness ◽  
Cost Effectiveness Analysis ◽  
Modified Release ◽  
2Nd Generation ◽  
Effectiveness Analysis ◽  
Sulfonylurea Drugs

In Russia, sulfonylurea drugs are extensively prescribed to patients with type 2 diabetes mellitus. This work was designed to study pharmacoeconomicaspects of application of 2nd generation sulfonylureas based on the results of the GUIDE study comparing effects of therapy with gliclazide modifiedrelease (diabeton MV) and glimepiride (amaryl). The two drugs are known to be equally effective, but gliclazide creates a much smaller risk ofhypoglycemia than glymepiride. Cost-effectiveness analysis showed that the use of gliclazide cuts the costs of therapy by 40%. It is concluded that thechoice of gliclazide modified release is economically more feasible than glimepiride.

Sign in / Sign up

Export Citation Format

Share Document